Daiichi Sankyo Company, Limited (TYO:4568)
3,673.00
+29.00 (0.80%)
Jul 24, 2025, 3:24 PM JST
Daiichi Sankyo Company Revenue
In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T JPY with 17.77% growth. Daiichi Sankyo Company had revenue of 518.69B in the quarter ending March 31, 2025, with 21.07% growth.
Revenue
1,886.26B
Revenue Growth
+17.77%
P/S Ratio
3.60
Revenue / Employee
95.43M
Employees
19,765
Market Cap
6,787.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,222.12B |
Takeda Pharmaceutical Company | 4,581.55B |
HOYA Corporation | 866.03B |
Terumo | 1,036.17B |
Otsuka Holdings | 2,393.18B |
Astellas Pharma | 1,912.32B |
Shionogi & | 438.27B |
Olympus | 997.33B |
Daiichi Sankyo Company News
- 6 days ago - AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
- 6 days ago - ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 4 weeks ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 4 weeks ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 5 weeks ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 6 weeks ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 7 weeks ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 7 weeks ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga